An Open-Label Study to Assess the Safety and Effect on Key Biomarkers of Oral RVX000222 in Subjects With Fabry Disease
Latest Information Update: 22 Nov 2023
At a glance
- Drugs Apabetalone (Primary)
- Indications Fabry's disease
- Focus Adverse reactions; Biomarker
- Sponsors Resverlogix Corporation
- 14 Nov 2023 Planned End Date changed from 30 Sep 2020 to 22 Nov 2022.
- 14 Nov 2023 Planned primary completion date changed from 30 Sep 2020 to 22 Nov 2022.
- 14 Nov 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.